The DOI matches its Crossref record; 161 of the 162 references it cites were found in a registry or an index.
Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer
Open accessAbstract
Radiotherapy is an important component of current treatment options for colorectal cancer (CRC). It is either applied as neoadjuvant radiotherapy to improve local disease control in rectal cancers or for the treatment of localized metastatic lesions of CRC. DNA double-strand breaks (DSBs) are the major critical lesions contributing to ionizing radiation (IR)-induced cell death. However, CRC stem cells promote radioresistance and tumor cell survival through activating cell-cycle checkpoints to trigger the DNA damage response (DDR) and DNA repair after exposure to IR. A promising strategy to overcome radioresistance is to target the DDR and DNA repair pathways with drugs that inhibit activated cell-cycle checkpoint proteins, thereby improving the sensitivity of CRC cells to radiotherapy. In this review, we focus on the preclinical studies and advances in clinical trials of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related kinase (ATR), checkpoint kinase 1 (CHK1), checkpoint kinase 2 (CHK2), WEE1 and poly (ADP-ribose) polymerase 1 (PARP1) kinase inhibitors in CRC. Importantly, we also discuss the selective radiosensitization of CRC cells provided by synthetic lethality of these inhibitors and the potential for widening the therapeutic window by targeting the DDR and DNA repair pathways in combination with radiotherapy and immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Radiotherapy (RT) causes DNA damage, and DDR inhibitors selectively mediate G2 checkpoint inhibition, allowing cells with unrepaired DNA to prematurely enter into mitosis, ultimately leading to mitotic catastrophe. DNA damage induces the release of damage-associated molecular pattern (DAMP) molecules. For example, HMGB1 is released into the extracellular environment and then mediates potent pro-inflammatory effects by binding to its downstream receptors such as Toll-like receptors (TLR) and receptors for advanced glycation end products (RAGE) to stimulate efficient processing and cross-presentation of tumor antigens from dying cells. Naive T cells differentiate into tumor-specific CD8+ T cells in response to type I interferon (IFN), leading to activation of anti-tumor immune responses and increased immunogenic cell death. On the other hand, DDR inhibition and mitotic death contribute to the formation of micronuclei, which is detected by cyclic GMP-AMP synthase (cGAS) and stimulate production of type I IFN as well as other inflammatory cytokines via the STING pathway, thereby triggering anti-tumor immune responses by CD8+ T cells. For the nomenclature of early cell death, regulated cell death, immunogenic cell death and mitotic catastrophe, please see the review by Galluzzi et al. [74].](https://figures.cochat.ai/paper-figures/fbee64940d46476c8736c03e7bf7f4d5/targeting-the-dna-damage-response-and-dna-repair-pathways-to-enhance-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Defective cell cycle checkpoints allow CRC cells to bypass damage-induced arrest and proceed through the cell cycle with damaged DNA [50].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, PARP inhibitors have also shown efficacy when used in combination with DNA-damaging agents such as chemotherapy and radiotherapy [50,134].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, various studies indicate that DDR inhibitors can sensitize CRC cells to the anticancer effects of chemotherapy and radiotherapy [50].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Global patterns and trends in colorectal cancer incidence and mortality
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310912 · Cited by 5,228
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597 · cited 1×
“The 5-year survival rate is >90% for patients with localized CRC but declines sharply to 11–15% for patients suffering from metastatic CRC (mCRC) [3].”
BackgroundESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 1×
“In addition, depending on the genotype of the tumor and its location, antibodies targeting the vascular endothelial growth factor (such as bevacizumab) or epidermal growth factor receptor (such as cetuximab) are added to the chemotherapy regimen [4,5].”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079 · cited 2×
“In recent years, immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have been shown to be effective in mCRC patients with DNA repair defects such as deficient mismatch repair (dMMR) or MSI-H CRC [144].”
BackgroundThe Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883 · cited 1×
“Drug resistance is driven by multiple factors, including increased drug efflux, overexpression of proteins related to DNA repair and suppression of proteins engaged in the apoptotic process [142].”
Background
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Defective cell cycle checkpoints allow CRC cells to bypass damage-induced arrest and proceed through the cell cycle with damaged DNA [50].”
New Horizons in Lung Cancer Management Through ATR/CHK1 Pathway Modulation
Thapa, R., Afzal, O., Bhat, A. A., Goyal, A., Altamimi, A. S. A., Almalki, W. H., Alzarea, A. I., Kazmi, I. A., Singh, S. K., Dua, K., et al. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0164 · Cited by 78
Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
Shen, J., Wang, Q., Mao, Y., Gao, W., & Duan, S. (2023) · MedComm · doi:10.1002/mco2.288 · Cited by 62
PARP inhibitors combined with radiotherapy: are we ready?
Sun, C., Chu, A., Song, R., Liu, S., Chai, T., Wang, X., & Liu, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1234973 · Cited by 52
Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy
Wang, X., Zhang, H., XinZhang, & Liu, Y. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00628-3 · Cited by 49
“The interplay between the DNA damage response and STING signaling within the tumor cells is critical in the formation of an inflammatory microenvironment that is governed by RT [67, 68].”
Background
Metadata
- Authors
- Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C.
- Affiliations
- Heidelberg University (DE)
- Corresponding author
- Herskind, Carsten
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-10-05
- Volume
- 14
- Issue
- 19
- Pages
- 4874
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9561988
- OpenAlex
- W4303621977
- Cited by
- 62
- References
- 162
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 12 · 2023: 10
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- China Scholarship Council (202106070027, 404521405)
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (202106070027, 404521405)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Keywords
- colorectal cancer, radiosensitization, DNA damage response, DNA repair, radioresistance (biology), DNA double-strand breaks, cell cycle checkpoints, DNA-PKcs inhibitor, ATM inhibitors, ATR inhibitors, CHK1 inhibitor, CHK2 inhibitors, WEE1 inhibitor, PARP-1 inhibitors, synthetic lethality, combination immunotherapy, rectal cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. https://app.cochat.ai/papers/10.3390/cancers14194874
- The paper
- Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C. (2022). Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. Cancers. https://doi.org/10.3390/cancers14194874
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.